Posted by Michael Wonder on 03 May 2017
Altor BioScience Corporation announces FDA fast track designation for lead candidate ALT-803 in patients with non-muscle invasive bladder cancer
2 May 2017 - Altor BioScience announced today that it has received fast track designation from the US FDA for its investigational interleukin-15 agonist complex, ALT-803, in combination with bacillus Calmette-Guérin, for the treatment of patients with non-muscle invasive bladder cancer.
The FDA’s fast track program is designed to expedite the development and review of drugs to treat serious conditions and fill unmet medical needs.
